| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the latest quarter, 4 analysts provided ratings for Guardant Health (NASDAQ:GH), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $37.75, a high estimate of $50.00, and a low estimate of $27.00. This current average has decreased by 19.68% from the previous average price target of $47.00.
The analysis of recent analyst actions sheds light on the perception of Guardant Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matthew Sykes | Goldman Sachs | Lowers | Buy | $37.00 | $43.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Buy | $37.00 | $43.00 |
| Andrew Cooper | Raymond James | Announces | Outperform | $27.00 | - |
| Shannon O'Callaghan | Morgan Stanley | Lowers | Overweight | $50.00 | $55.00 |
Capture valuable insights into Guardant Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Guardant Health analyst ratings.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Guardant Health's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 21.83%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Guardant Health's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -60.2%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Guardant Health's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -33.05%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Guardant Health's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.73%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Guardant Health's debt-to-equity ratio surpasses industry norms, standing at 5.95. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: GH
